Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | DEFA14A: Others
Cerevel Therapeutics Holdings | DEFM14A: Definitive proxy statement relating to merger or acquisition
Cerevel Therapeutics Holdings | DEFA14A: Others
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
Cerevel Therapeutics Holdings | DEFA14A: Others
Cerevel Therapeutics Holdings | DEF 14A: Definitive proxy statements
Cerevel Therapeutics Holdings | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Cerevel Therapeutics Holdings | 8-K: Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | 8-K: Current report
Cerevel Therapeutics Holdings | S-3: Registration statement for specified transactions by certain issuers
Cerevel Therapeutics Holdings | 8-K: Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
No Data